Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Achieving antigen-specific tolerance in diabetes: regulating specifically.

Wei Chen1, Jeffrey A Bluestone, Kevan C Herold

  • 1Naomi Berrie Diabetes Center and the Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA. kh318@columbia.edu

International Reviews of Immunology
|December 2, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacology and nonclinical development of teplizumab, a first-in-class immunotherapy for delaying the onset of type 1 diabetes.

The Journal of pharmacology and experimental therapeutics·2026
Same author

Tet2 modulates ER stress responses related to β-cell death and autoimmunity in diabetes.

iScience·2026
Same author

Predicting checkpoint inhibitor-associated autoimmune diabetes: prospects and limitations.

The Journal of clinical investigation·2026
Same author

Anti-CD3 mAb treatment reshapes infiltrating T and β cells in the islets in autoimmune diabetes.

JCI insight·2026
Same author

Phase I Clinical Trial of Islet Antigen-Specific Plasmid Coexpressing Tolerogenic Proteins Demonstrates Safety in Adults With Type 1 Diabetes.

Diabetes·2026
Same author

Gene-corrected regulatory T cell therapy for IL2RA deficiency.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Regulatory mechanisms, including regulatory T cells, can halt autoimmune diseases like type 1 diabetes. Harnessing these mechanisms offers potential for antigen-specific adoptive immune therapy.

Area of Science:

  • Immunology
  • Autoimmunity
  • T cell regulation

Background:

  • Autoreactive T cells normally are controlled by regulatory mechanisms to prevent self-attack.
  • Regulatory T cells (Tregs) can be induced by treatments like anti-CD3 monoclonal antibodies (mAbs) to suppress ongoing immune responses.
  • Current Treg induction methods are not antigen-specific, limiting their therapeutic application.

Purpose of the Study:

  • To review the mechanisms underlying anti-CD3 mAb-induced immune regulation.
  • To explore how understanding these mechanisms can inform the development of antigen-specific adoptive immune therapies.
  • To discuss the potential of Treg-based therapies for type 1 diabetes and other autoimmune diseases.

Main Methods:

  • Review of existing literature on anti-CD3 mAb treatment and T cell regulation.

Related Experiment Videos

  • Analysis of TGF-beta dependent and independent regulatory pathways involving CD4+ and CD8+ T cells.
  • Discussion of strategies for achieving antigen-specific Treg induction and sustained tolerance.

    • Main Results:

    • Anti-CD3 mAbs can induce regulatory T cells (Tregs) through various mechanisms.
    • Both CD4+ and CD8+ T cells play roles in TGF-beta dependent and independent regulation.
    • Achieving antigen-specific Treg induction is crucial for lasting autoimmune tolerance.

    Conclusions:

    • Understanding anti-CD3 mAb mechanisms provides insights into Treg induction.
    • Antigen-specific adoptive immunotherapy with Tregs holds promise for treating autoimmune diseases.
    • Further research is needed to translate these findings into effective clinical therapies for type 1 diabetes.